Indian pharmaceutical company major, and a part of the Cadila Healthcare group, Zydus Cadila Limited on Thursday said it has received tentative approval from the US health regulator to market Linagliptin tablets, used to treat type 2 diabetes in adults. Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Linagliptin tablets in the strength of 5 mg, it said in the stock exchange filing.
The company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 310 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in the financial year 2003-04. Linagliptin tablets are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Cadila Healthcare Limited has not impacted in its share price with this development. During noon session of trade, Shares of Cadila Healthcare were quoting at Rs. 415 per share, down by Rs.3.35 from is previous closing on the National Stock Exchange. N comparison, the BSE Sensex stood at 39697 level down by 229 points and the NSE Nifty clocked at 11650, down by 79 points in trade.
Cadila Healthcare Plans to Boost Capacity by 70pc
MCX Gold Watch: Gold Steady, Silver Could Decline Further
Market Morning pulls: Nifty breaches 11,700 level